Skip to main content
Premium Trial:

Request an Annual Quote

Baylor, Berry Genomics Team on Non-invasive Prenatal Dx

NEW YORK (GenomeWeb News) – Baylor College of Medicine said on Thursday that it will partner with the Chinese prenatal testing company Berry Genomics to combine their capabilities to improve prenatal genetic testing methods.

The partners plan to harness BCM's gene-chip microarray technologies that assess chromosome structure and Berry Genomics' technologies, which are used to evaluate fetal DNA in maternal plasma.

Testing using samples from fetal DNA from the mother's plasma gives patients the option of avoiding invasive procedures, such as placental or amniocentesis tests, which carry some risks and can be a source of stress for expecting mothers.

"We are conducting research to enable non-invasive prenatal testing to detect all the conditions currently detected by invasive testing," Arthur Beaudet, chair and professor of molecular genetics at BCM, said in a statement.

"Non-invasive prenatal testing and microarray technology are rapidly changing the way we detect genetic diseases," explained Berry Genomics' CEO Daixing Zhou, who added that this collaboration aims to enable them to "offer complete solutions for prenatal screening and diagnosis."

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.